15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 26 firms covering Biogen Inc, 16 rate it Buy or better, 9 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $150.00 to $300.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $236.40 sits 11% above the current $212.41. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 14 to 15 over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.27 next quarter toward $16.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS26 ratings
Moderate Buy
Strong Buy00%
Buy1662%
Hold935%
Sell14%
Strong Sell00%
Based on 26 analysts giving stock ratings to Biogen Inc.
As of Sep, 15 of 25 firms rate BIIB a Buy (9 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
BIIB EPS & revenue forecast
EPS · NEXT QUARTER
$3.27
Range $2.77 – $3.87 · 26 analysts · +64% YoY
Next period, 26 analysts expect Biogen Inc to earn $3.27 a share (range $2.77 – $3.87), versus $1.99 a year earlier. Full-year consensus is $12.61, growing to $16.54 the year after.
REVENUE · NEXT QUARTER
$2.6B
Range $2.4B – $2.7B · 26 analysts · +14% YoY
Revenue is expected to reach $2.6B (range $2.4B – $2.7B), +13.9% year-over-year. Full-year consensus is $10.4B, rising to $10.7B next year.
Top analysts covering Biogen Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BIIB.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$280.00+31.8% to target
Overall win rate
53%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$251.00+18.2% to target
Overall win rate
46%
+ Follow
#3
Ami Fadia
Needham · Rank #67
Buy
$256.00+20.5% to target
Overall win rate
47%
+ Follow
#4
Laura Chico
Wedbush · Rank #74
Hold
$215.00+1.2% to target
Overall win rate
44%
+ Follow
#5
David Amsellem
Piper Sandler · Rank #107
Buy
$245.00+15.3% to target
Overall win rate
50%
+ Follow
BIIB stock forecast FAQ
What is BIIB's average 12-month price target?+
The 20 analysts with a live target average $236.40 for Biogen Inc over the next 12 months, ranging from a $300.00 high to a $150.00 low.
Is BIIB stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 26 analyst ratings, 16 are Buy or Strong Buy, 9 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for BIIB?+
The Street-high target is $300.00 (Wolfe Research), and the Street-low is $150.00 (HSBC). The average of all 20 active targets is $236.40.
How many Wall Street analysts cover BIIB?+
26 analysts have an active rating on Biogen Inc, and 20 firms carry a live 12-month price target.
Who is the most accurate analyst covering BIIB?+
Among analysts who currently cover BIIB, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $280.00 target.
What is Biogen Inc's projected EPS for next quarter?+
The consensus estimate is $3.27 per share (range $2.77 – $3.87) across 26 analysts. Full-year EPS is projected at $12.61, rising to $16.54 the following year.
How much revenue is Biogen Inc expected to report next quarter?+
Consensus revenue is $2.6B (range $2.4B – $2.7B). Full-year revenue is projected at $10.4B, growing to $10.7B next year.
Have analysts been upgrading or downgrading BIIB lately?+
As of Sep, 15 of 25 firms rate BIIB a Buy (9 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BIIB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
